Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (PIRA). That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. This approach targets the underlying mechanisms that contribute to disability accumulation, potentially offering a new paradigm in MS treatment.
The importance of this shift cannot be overstated. As the understanding of MS evolves, the focus on PIRA and chronic active lesions represents a significant departure from traditional relapse-centric models. By addressing these drivers, therapies like Lucid-MS could potentially slow or halt disability progression, improving long-term outcomes for patients.
Quantum BioPharma is at the forefront of this innovative approach, with Lucid-MS aiming to provide a disease-modifying therapy that goes beyond symptomatic relief. The company’s commitment to targeting myelin preservation and functional recovery could set a new standard in MS care.
For more information on the latest news and updates relating to QNTM, visit the company’s newsroom at https://ibn.fm/QNTM. Investors are encouraged to review the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
